A part of Watch Media

MedWatchTuesday3 October 2023

  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
MedWatchTuesday3 October 2023
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
News

Galecto fetches former CEO from Aimmune for board

After getting listed on the US stock exchange, Galecto has gained the former CEO of Aimmune Therapeutics, which was acquired by Nestlé's health division earlier in the year.
Photo: Fabrice Coffrini/AFP/Ritzau Scanpix
Photo: Fabrice Coffrini/AFP/Ritzau Scanpix
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

Galecto's listing in the US stock exchange has lead to some changes for the Danish biotech firm.

The people behind the Danish Capital fund Sunstone Life Science recently stepped out of its board and it seems Galecto has found their replacement. Because Galecto has announced that it has gained a new member of the board in Jayson Dallas.

Most recently, Jayson Dallas was the Presiden & CEO at the biotech Aimmune Therapeutics, which has garnered attention for its work towards finding a treatment for peanut allergy. The company was sold to Nestlé's health division earlier in the year, after which Jayson Dallas also left the firm.

I am delighted to welcome Jayson to the Galecto Board of Directors. His expertise in all aspects of the healthcare industry, from biotech to big pharma and drug development to commercialization, will be an important source of knowledge and guidance for Galecto as we continue through an exciting period of growth."

After Galecto became listed on the stock exchange, the firm has found a solid financial foundation – shortly before getting listed, the company fetched some money from private investors – and as such the firm expects to start all of three phase II trials in the next couple of months.

Would you like to receive the latest news from MedWatch directly in your e-mail inbox? Sign up for our free English newsletter below.

New Nordic fund prone for second investment – pours millions into antiviral spinout 

Venture veterans raise EUR 76 million for new life science fund 

Novo Seeds partner wants to raise millions for Nordic life science: "There is a dire need" 

Share article

Related articles:

  • Thomas N. Kledal (right), co-founder and CEO of Synklino; John Haurum (left), Synklino's chair. | Photo: Synklino / PR

    New Nordic fund prone for second investment – pours millions into antiviral spinout

    For subscribers

  • The founders of Eir Ventures: Stephan Christgau, Amanda Hayward, Andreas Rutger Segerros and Magnus Persson. | Photo: trmedia.dk

    Venture veterans raise EUR 76 million for new life science fund

    For subscribers

  • Photo: PR / Novo Seeds

    Novo Seeds partner wants to raise millions for Nordic life science: "There is a dire need"

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Foto: Tom Little
Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.
  • FDA to review Novo Nordisk drug for rare metabolic disease
  • Huge acquisition scores Novo Nordisk an FDA-ready treatment

For subscribers



Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Foto: Liselotte Plenov / Fotorummet / Pr
Pharma & biotech

Fujifilm expands management with former Leo executive

For subscribers



Foto: Andrew Kelly/Reuters/Ritzau Scanpix
Pharma & biotech

Low share price may knock Galecto off the stock exchange

For subscribers


Foto: Mike Segar/Reuters/Ritzau Scanpix
Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug


Foto: Yuriko Nakao/Reuters/Ritzau Scanpix
Medtech

Olympus appoints new chief medical officer

For subscribers


Foto: Alexander Heinl/AP/Ritzau Scanpix
Pharma & biotech

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics

For subscribers


  • Vaccine breakthrough behind mRNA shots wins Nobel Prize

    The two scientists will share the 11 million-krona ( USD 1 million) award, the Nobel Assembly at the Karolinska Institutet in Stockholm said in a statement Monday.

    For subscribers


  • Foto: Ws Audiology / Pr

    WS Audiology hires new chief technology officer from car manufacturer

    He succeeds chief research & development officer Stefan Menzl, who is stepping down after six years.

    For subscribers


  • Foto: Tom Little

    Novo Nordisk files lawsuit against US authorities ahead of price negotiation

    The litigation is the latest in a long line of industry lawsuits related to price negotiations.

    For subscribers


  • Foto: Mike Segar

    FDA rejects atopic dermatitis drug lebrikizumab

    Eli Lilly had expected a launch this year.

    For subscribers


  • The FDA has updated the package label of Novo Nordisk's diabetes drug, Ozempic, with a warning about intestinal blockage disorder as a possible side effect. | Foto: Tom Little/Reuters/Ritzau Scanpix

    FDA updates Novo Nordisk's Ozempic drug label with side effect alert

    The diabetes drug might cause a potentially fatal intestinal blockage, the authorities warn.

    For subscribers


  • Foto: Anushree Fadnavis/Reuters/Ritzau Scanpix

    Country Manager: Indians will have to wait for Wegovy until 2026

    Up to 40% of the female population aged 30-49 in India is overweight.

    For subscribers


Further reading

Foto: Tom Little
Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers



Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Foto: Liselotte Plenov / Fotorummet / Pr
Pharma & biotech

Fujifilm expands management with former Leo executive

The contract manufacturer has hired a chief people officer with immediate effect.

For subscribers



Foto: Mike Segar/Reuters/Ritzau Scanpix
Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug

”As with anything that could potentially impact our business, we’re looking at it,” says the former Kellogg’s CEO.

Foto: Alexander Heinl/AP/Ritzau Scanpix
Pharma & biotech

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics

Previous studies have shown that alcohol cravings disappeared when people were treated with GLP-1 agonist exanatide.

For subscribers



Genmab CEO Jan van de Winkel and director general of The Confederation of Danish Industry, Lars Sandahl Sørensen. | Foto: Genmab / PR
Pharma & biotech

Genmab has officially opened its new headquarters

The CEO describes the new premises as a symbol of the company’s commitment to advancing science and innovation.

For subscribers



Foto: Yuriko Nakao/Reuters/Ritzau Scanpix
Medtech

Olympus appoints new chief medical officer

The new medical director is brought in from Medtronic. 

For subscribers


Jobs

  • Senior QA Specialists (GMP or GCP)

  • Global Medical Manager

  • Audit & Supplier Manager

  • VP of Software Development, Perfusion Tech

  • QA/RA Manager

  • Senior Analytical Scientists

  • Supply Value Stream (SVS) Project Manager

  • Scientist - Bioanalysis, Biologics

  • Senior Legal Councel

  • Clinical Supply Manager

  • Senior CMC Specialist, Upstream Processing, Genmab

  • Project Director, HR & ESG

  • Clinical Trial Manager

  • Qualified Person to AJ Vaccines

  • Director, Head of Antibody Technology

See all jobs

Latest news

  • Novo Nordisk's semaglutide to be studied for positive effect on alcoholics –
  • Olympus appoints new chief medical officer –
  • Low share price may knock Galecto off the stock exchange –
  • Fujifilm expands management with former Leo executive –
  • Snack maker keeps an eye on Novo Nordisk's obesity drug –
  • FDA approves Novo Nordisk drug to treat rare condition –
  • FDA updates Novo Nordisk's Ozempic drug label with side effect alert –
  • FDA rejects atopic dermatitis drug lebrikizumab –
  • FDA to support new orphan drugs through pilot program –
  • Vaccine breakthrough behind mRNA shots wins Nobel Prize –
See all

Jobs

  • Senior QA Specialists (GMP or GCP)

  • Global Medical Manager

  • Audit & Supplier Manager

  • VP of Software Development, Perfusion Tech

  • QA/RA Manager

  • Senior Analytical Scientists

  • Supply Value Stream (SVS) Project Manager

  • Scientist - Bioanalysis, Biologics

  • Senior Legal Councel

  • Clinical Supply Manager

  • Senior CMC Specialist, Upstream Processing, Genmab

  • Project Director, HR & ESG

  • Clinical Trial Manager

  • Qualified Person to AJ Vaccines

  • Director, Head of Antibody Technology

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

  • About MedWatch

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Banner Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved